Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leuprolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.86 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.84 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.79 |
| ▸ | APLNR | P35414 | 4/20 | 0.64 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leuprolide SCHEMBL7751433 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL10061885 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL21540132 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL4585 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Deslorelin SCHEMBL1649660 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL3915060 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| SCHEMBL21109135 | 0.98 | GNRHR (0.84) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL570851 | 0.98 | ABCC2 (0.87) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL847084 | 0.98 | ABCC2 (0.87) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL3174 | 0.98 | ABCC2 (0.87) | GNRHRABCC2PTGS1APLNRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10561734-B2 | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions | OAKWOOD LABORATORIES (US) | 2020-02-18 | — | — | US | disclosed |
| US-20160310601-A1 | PREVENTION OF MOLECULAR WEIGHT REDUCTION OF THE POLYMER, IMPURITY FORMATION AND GELLING IN POLYMER COMPOSITIONS | OAKWOOD LABORATORIES | 2016-10-27 | — | — | US | disclosed |
| EP-1660039-B1 | PREVENTION OF MOLECULAR WEIGHT REDUCTION OF THE POLYMER, IMPURITY FORMATION AND GELLING IN POLYMER COMPOSITIONS | OAKWOOD LAB L L C (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9017715-B2 | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions | OAKWOOD LABORATORIES, L.L.C. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20130165377-A1 | PREVENTION OF MOLECULAR WEIGHT REDUCTION OF THE POLYMER, IMPURITY FORMATION AND GELLING IN POLYMER COMPOSITIONS | OAKWOOD LABORATORIES, LLC (US) | 2013-06-27 | — | — | US | disclosed |
| US-8343513-B2 | Mixture of polymer and drug with acid adjuvant | OAKWOOD LABORATORIES, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2462923-A2 | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions | Oakwood Laboratories L.L.C. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20050042294-A1 | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions | ALFERA PHARMACEUTICALS, LLC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165377-A1 | PREVENTION OF MOLECULAR WEIGHT REDUCTION OF THE POLYMER, IMPURITY FORMATION AND GELLING IN POLYMER COMPOSITIONS | GNRHR, PDE7A, ADCYAP1R1 | GNRHR 1/4885ABCC2 3823/4885PTGS1 216/4885 |
| US-20160310601-A1 | PREVENTION OF MOLECULAR WEIGHT REDUCTION OF THE POLYMER, IMPURITY FORMATION AND GELLING IN POLYMER COMPOSITIONS | GNRHR, PDE7A, ADCYAP1R1 | GNRHR 1/4885ABCC2 3823/4885PTGS1 216/4885 |
| US-20050042294-A1 | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions | GNRHR, PDE7A, ADCYAP1R1 | GNRHR 1/4885ABCC2 3823/4885PTGS1 216/4885 |
| US-10561734-B2 | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions | GNRHR, PDE7A, ADCYAP1R1 | GNRHR 1/4885ABCC2 3823/4885PTGS1 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.